Dyne Therapeutics Inc. presented their most recent work to advance novel therapeutics for facioscapulohumeral muscular dystrophy (FHSD). FSHD is an autosomal dominant genetic disorder characterized by ...
Dyne Therapeutics Inc. is advancing novel therapeutics for people living with genetically driven neuromuscular diseases.
Oxford Mail on MSN4d
PhD student with muscle-wasting condition to start Oxford 10kA PhD student with limb girdle muscular dystrophy will be the official race starter for this year's Oxford 10k.
For disability activist Jang Ik-sun, hope isn't just a feeling — it’s the eye-tracking software he has mastered to draft ...
New research led by the University of Portsmouth has revealed how Duchenne muscular dystrophy (DMD), best known for causing ...
The 11-year-old's strength and bravery in living with the impact of the serious muscle-wasting condition was hailed by her ...
Rachel Kondo, creator and head writer of the hit series Shogun, has never shied away from confronting life’s most difficult ...
Convener of Stirling Council’s Children and Young People Committee, Cllr Danny Gibson said: “Somhairle’s bravery, inner strength and positivity in the face of this serious condition has had a major ...
After Sarepta reported the death of a patient who had recently taken the gene therapy Elevidys, patient advocacy group Parent ...
Capricor Therapeutics (CAPR) released expectation-beating results for the fourth quarter, sending the shares up over 5% in aftermarket trading.
After bringing Zolgensma to market in 2019 as the first gene therapy for spinal muscular atrophy, Novartis is back with an intrathecal formulation intended for older patients.
Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback